Endpoints News 5. Mai 2026 Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't want
Endpoints News 4. Mai 2026 Celcuity breast cancer win; Odyssey plans $205M IPO; Latus Bio extends Series A
Endpoints News 4. Mai 2026 Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial
Endpoints News 1. Mai 2026 FDA approves Pfizer and Arvinas' breast cancer drug despite underwhelming data
Endpoints News 1. Mai 2026 Amgen launches late-stage obesity trial in patients who switch from rival drugs
Endpoints News 1. Mai 2026 Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research
Endpoints News 1. Mai 2026 Acelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China